Skip to content

Company Science Publications Program Team News & Events Contact

Kevin Combs

Chief Executive Officer and Chairman

Kevin Combs serves as Chief Executive Officer and Chairman of NK Immuno T.

← Back to Our Team

NK Immuno T’s technology is licensed from the University of California, Los Angeles (UCLA), through the UCLA Technology Development Group.

Program status: Investigational preclinical program. Not approved for clinical use. Clinical safety and efficacy have not been established. This website does not provide medical advice or clinical care. Please do not send personal health information.

Company Research library Team Contact

© 2026 NK Immuno TTeam Email ↗

Biomarker-guided ALS therapeutic program